Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.07.23.218602v1?rss=1
Authors: Foox, J., Tighe, S. W., Nicolet, C. M., Zook, J. M., Byrska-Bishop, M., Clarke, W. E., Khayat, M. M., Mahmoud, M., Laaguiby, P. K., Herbert, Z. T., Warner, D., Grills, G. S., Levy, S., Schroth, G. P., Sedlazeck, F. J., Narzisi, G., Farmerie, W., Baldwin, D. A., Mason, C. E., Mason, C.
Abstract:
Massively parallel DNA sequencing is a critical tool for genomics research and clinical diagnostics. Here, we describe the Association of Biomolecular Resource Facilities (ABRF) Next-Generation Sequencing Phase II Study to measure quality and reproducibility of DNA sequencing. Replicates of human and bacterial reference DNA samples were generated across multiple sequencing platforms, including well-established technologies such as Illumina, ThermoFisher Ion Torrent, and Pacific Biosciences, as well as emerging technologies such as BGI, Genapsys, and Oxford Nanopore. A total of 202 datasets were generated to investigate the performance of a total of 16 sequencing platforms, including mappability of reads, coverage and error rates in difficult genomic regions, and detection of small-scale polymorphisms and large-scale structural variants. This study provides a comprehensive baseline resource for continual benchmarking as chemistries, methods, and platforms evolve for DNA sequencing.
Copy rights belong to original authors. Visit the link for more info